Conduit Pharmaceuticals I... (CDT)
Conduit Pharmaceuticals Statistics
Share Statistics
Conduit Pharmaceuticals has 9.55M shares outstanding. The number of shares has increased by 537.58% in one year.
| Shares Outstanding | 9.55M |
| Shares Change (YoY) | 537.58% |
| Shares Change (QoQ) | 292.73% |
| Owned by Institutions (%) | 0.21% |
| Shares Floating | 8.35M |
| Failed to Deliver (FTD) Shares | 12.35K |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 451.05K, so 4.72% of the outstanding shares have been sold short.
| Short Interest | 451.05K |
| Short % of Shares Out | 4.72% |
| Short % of Float | 5.4% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 1.41 and the forward PE ratio is null. Conduit Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 1.41 |
| Forward PE | n/a |
| PS Ratio | 0.3 |
| Forward PS | null |
| PB Ratio | -41.1 |
| P/FCF Ratio | -28.68 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Conduit Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25, with a Debt / Equity ratio of -1.1.
| Current Ratio | 0.25 |
| Quick Ratio | 0.25 |
| Debt / Equity | -1.1 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | -0.77 |
| Interest Coverage | -6.96 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $153.7M |
| Profits Per Employee | $33.07M |
| Employee Count | 6 |
| Asset Turnover | 219.94 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -29.53M |
| Effective Tax Rate | -12.95% |
Stock Price Statistics
The stock price has increased by -99.71% in the last 52 weeks. The beta is 2.35, so Conduit Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.35 |
| 52-Week Price Change | -99.71% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 12.11 |
| Relative Strength Index (RSI) | 45 |
| Average Volume (20 Days) | 5.59M |
Income Statement
In the last 12 months, Conduit Pharmaceuticals had revenue of 922.22M and earned 198.43M in profits. Earnings per share was 4.88.
| Revenue | 922.22M |
| Gross Profit | 922.22M |
| Operating Income | 266.46M |
| Net Income | 198.43M |
| EBITDA | 266.46M |
| EBIT | 189.64M |
| Earnings Per Share (EPS) | 4.88 |
Balance Sheet
The company has 554K in cash and 7.46M in debt, giving a net cash position of -6.9M.
| Cash & Cash Equivalents | 554K |
| Total Debt | 7.46M |
| Net Cash | -6.9M |
| Retained Earnings | -29.1M |
| Total Assets | 4.19M |
| Working Capital | 1.19B |
Cash Flow
In the last 12 months, operating cash flow was -9.68M and capital expenditures -51K, giving a free cash flow of -9.73M.
| Operating Cash Flow | -9.68M |
| Capital Expenditures | -51K |
| Free Cash Flow | -9.73M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 100%, with operating and profit margins of 28.89% and 21.52%.
| Gross Margin | 100% |
| Operating Margin | 28.89% |
| Pretax Margin | 24.72% |
| Profit Margin | 21.52% |
| EBITDA Margin | 28.89% |
| EBIT Margin | 28.89% |
| FCF Margin | -1.06% |
Dividends & Yields
CDT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CDT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 27, 2025. It was a backward split with a ratio of 1:100.
| Last Split Date | Jan 27, 2025 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | 1186.64 |
| Piotroski F-Score | 4 |